CN101632714A - 用于降低血糖的药物组合物 - Google Patents
用于降低血糖的药物组合物 Download PDFInfo
- Publication number
- CN101632714A CN101632714A CN200910081657A CN200910081657A CN101632714A CN 101632714 A CN101632714 A CN 101632714A CN 200910081657 A CN200910081657 A CN 200910081657A CN 200910081657 A CN200910081657 A CN 200910081657A CN 101632714 A CN101632714 A CN 101632714A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- magnesium
- calcium
- zinc
- chromium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 Blood Anatomy 0.000 title claims abstract description 35
- 239000008280 blood Substances 0.000 title claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract description 11
- 239000008103 glucose Substances 0.000 title abstract description 11
- 230000001603 reducing Effects 0.000 title abstract description 8
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 89
- 239000011720 vitamin B Substances 0.000 claims abstract description 89
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 48
- 239000011651 chromium Substances 0.000 claims abstract description 43
- 235000012721 chromium Nutrition 0.000 claims abstract description 41
- 239000011777 magnesium Substances 0.000 claims abstract description 41
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 40
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 40
- 229960003471 retinol Drugs 0.000 claims abstract description 37
- 239000011701 zinc Substances 0.000 claims abstract description 34
- 239000011575 calcium Substances 0.000 claims abstract description 33
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 33
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 32
- 235000001465 calcium Nutrition 0.000 claims abstract description 32
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 31
- 239000011669 selenium Substances 0.000 claims abstract description 31
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 31
- 239000011718 vitamin C Substances 0.000 claims abstract description 31
- 150000003700 vitamin C derivatives Chemical class 0.000 claims abstract description 31
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 30
- 229940046009 Vitamin E Drugs 0.000 claims abstract description 30
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 30
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 30
- 239000011709 vitamin E Substances 0.000 claims abstract description 30
- 150000003712 vitamin E derivatives Chemical class 0.000 claims abstract description 29
- 229940046008 Vitamin D Drugs 0.000 claims abstract description 28
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 28
- 239000011572 manganese Substances 0.000 claims abstract description 28
- ZOKXTWBITQBERF-UHFFFAOYSA-N molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000011733 molybdenum Substances 0.000 claims abstract description 28
- 229910052750 molybdenum Inorganic materials 0.000 claims abstract description 28
- 235000016768 molybdenum Nutrition 0.000 claims abstract description 28
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 28
- 239000011710 vitamin D Substances 0.000 claims abstract description 28
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 27
- 235000002908 manganese Nutrition 0.000 claims abstract description 27
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 27
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 26
- 229940045997 Vitamin A Drugs 0.000 claims abstract description 26
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 26
- 239000011719 vitamin A Substances 0.000 claims abstract description 26
- 229960002747 Betacarotene Drugs 0.000 claims abstract description 24
- OENHQHLEOONYIE-VYAWBVGESA-N beta-Carotene Natural products CC=1CCCC(C)(C)C=1\C=C\C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-VYAWBVGESA-N 0.000 claims abstract description 24
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 24
- 239000011648 beta-carotene Substances 0.000 claims abstract description 24
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 24
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229930003270 Vitamin B Natural products 0.000 claims description 88
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 39
- 239000010949 copper Substances 0.000 claims description 31
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 30
- 229910052802 copper Inorganic materials 0.000 claims description 30
- 229940055726 Pantothenic Acid Drugs 0.000 claims description 24
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 24
- 229960002079 calcium pantothenate Drugs 0.000 claims description 24
- 235000019161 pantothenic acid Nutrition 0.000 claims description 24
- 239000011713 pantothenic acid Substances 0.000 claims description 24
- GHOKWGTUZJEAQD-ZETCQYMHSA-N pantothenic acid Natural products OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 24
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 23
- 229960002685 biotin Drugs 0.000 claims description 22
- 235000020958 biotin Nutrition 0.000 claims description 22
- 239000011616 biotin Substances 0.000 claims description 22
- 229960000304 Folic Acid Drugs 0.000 claims description 19
- 235000019152 folic acid Nutrition 0.000 claims description 19
- 239000011724 folic acid Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 13
- 235000020944 retinol Nutrition 0.000 claims description 11
- 239000011607 retinol Substances 0.000 claims description 11
- 229940079593 drugs Drugs 0.000 claims description 9
- 235000013619 trace mineral Nutrition 0.000 abstract description 46
- 239000011573 trace mineral Substances 0.000 abstract description 46
- 230000000694 effects Effects 0.000 abstract description 28
- 201000001421 hyperglycemia Diseases 0.000 abstract description 6
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 229940046001 Vitamin B Complex Drugs 0.000 abstract 1
- 229940091250 Magnesium supplements Drugs 0.000 description 32
- 239000000203 mixture Substances 0.000 description 28
- 229940046282 Zinc Drugs 0.000 description 25
- 229940091251 Zinc Supplements Drugs 0.000 description 25
- 229960005069 Calcium Drugs 0.000 description 24
- 229940108928 Copper Drugs 0.000 description 23
- GVJHHUAWPYXKBD-IEOSBIPESA-N alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 229940091258 Selenium supplements Drugs 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 239000000654 additive Substances 0.000 description 11
- 229940087168 alpha Tocopherol Drugs 0.000 description 11
- 229960000984 tocofersolan Drugs 0.000 description 11
- 239000002076 α-tocopherol Substances 0.000 description 11
- 235000004835 α-tocopherol Nutrition 0.000 description 11
- 230000036740 Metabolism Effects 0.000 description 10
- 230000000996 additive Effects 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- 230000035786 metabolism Effects 0.000 description 10
- 229940107218 Chromium Drugs 0.000 description 9
- 229940082568 Selenium Drugs 0.000 description 9
- MHQOTKLEMKRJIR-UHFFFAOYSA-L Sodium selenate Chemical compound [Na+].[Na+].[O-][Se]([O-])(=O)=O MHQOTKLEMKRJIR-UHFFFAOYSA-L 0.000 description 9
- RMRCNWBMXRMIRW-WYVZQNDMSA-L Vitamin B12 Chemical compound N([C@@H]([C@@]1(C)[C@@](C)(CC(N)=O)[C@H](CCC(N)=O)\C(N1[Co+]C#N)=C(/C)\C1=N\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NCC(C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO RMRCNWBMXRMIRW-WYVZQNDMSA-L 0.000 description 9
- 229940050168 ZINC LACTATE Drugs 0.000 description 9
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 9
- 230000003203 everyday Effects 0.000 description 9
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 9
- 239000011655 sodium selenate Substances 0.000 description 9
- 235000018716 sodium selenate Nutrition 0.000 description 9
- 229960001881 sodium selenate Drugs 0.000 description 9
- 239000011576 zinc lactate Substances 0.000 description 9
- 235000000193 zinc lactate Nutrition 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 229910000323 aluminium silicate Inorganic materials 0.000 description 8
- KZHJGOXRZJKJNY-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Si]=O.O=[Al]O[Al]=O.O=[Al]O[Al]=O.O=[Al]O[Al]=O KZHJGOXRZJKJNY-UHFFFAOYSA-N 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- STDMRMREKPZQFJ-UHFFFAOYSA-H tricopper;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Cu+2].[Cu+2].[Cu+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O STDMRMREKPZQFJ-UHFFFAOYSA-H 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- OVGXLJDWSLQDRT-UHFFFAOYSA-L Magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- -1 lipid peroxide Chemical class 0.000 description 7
- 235000015229 magnesium lactate Nutrition 0.000 description 7
- 239000000626 magnesium lactate Substances 0.000 description 7
- 229960004658 magnesium lactate Drugs 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229940107161 Cholesterol Drugs 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- TVXXNOYZHKPKGW-UHFFFAOYSA-N Sodium molybdate Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cells Anatomy 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 235000014872 manganese citrate Nutrition 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000011684 sodium molybdate Substances 0.000 description 6
- 235000015393 sodium molybdate Nutrition 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229930003231 vitamins Natural products 0.000 description 6
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 description 5
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 5
- 206010012601 Diabetes mellitus Diseases 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 229940097206 MANGANESE CITRATE Drugs 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 5
- 229940088594 Vitamin Drugs 0.000 description 5
- 230000002708 enhancing Effects 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000011564 manganese citrate Substances 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- HIMXGTXNXJYFGB-UHFFFAOYSA-N Alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002496 gastric Effects 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 210000000988 Bone and Bones Anatomy 0.000 description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L Calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 3
- 229940096919 Glycogen Drugs 0.000 description 3
- BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 235000011086 calcium lactate Nutrition 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000020828 fasting Nutrition 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- AOHMFUYIHARAGR-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;magnesium Chemical compound [Mg].[Mg].[Mg].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O AOHMFUYIHARAGR-UHFFFAOYSA-N 0.000 description 2
- 208000007502 Anemia Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 229940046374 CHROMIUM PICOLINATE Drugs 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 208000008787 Cardiovascular Disease Diseases 0.000 description 2
- CBDQOLKNTOMMTL-UHFFFAOYSA-K Chromium(III) picolinate Chemical compound [N]12=CC=CC=C2C(=O)O[Cr]112([N]3=CC=CC=C3C(=O)O1)[N]1=CC=CC=C1C(=O)O2 CBDQOLKNTOMMTL-UHFFFAOYSA-K 0.000 description 2
- 208000001590 Congenital Abnormality Diseases 0.000 description 2
- 102000010909 EC 1.4.3.4 Human genes 0.000 description 2
- 108010062431 EC 1.4.3.4 Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 208000005368 Osteomalacia Diseases 0.000 description 2
- 241000338310 Pseudofabraea citricarpa Species 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 210000002356 Skeleton Anatomy 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003064 anti-oxidating Effects 0.000 description 2
- 230000003078 antioxidant Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- 231100000406 dermatitis Toxicity 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000745 gonadal hormone Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000002607 hemopoietic Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000002538 magnesium citrate Nutrition 0.000 description 2
- 239000004337 magnesium citrate Substances 0.000 description 2
- 229960005336 magnesium citrate Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001537 neural Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 230000001850 reproductive Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- LGGKLHHIIOOPKS-WCCKRBBISA-N (2S)-2-amino-4-methylsulfanylbutanoic acid;zinc Chemical compound [Zn].CSCC[C@H](N)C(O)=O LGGKLHHIIOOPKS-WCCKRBBISA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- XMLHTAFIAXPIDG-UHFFFAOYSA-K 2-hydroxypropane-1,2,3-tricarboxylate;manganese(3+) Chemical class [Mn+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XMLHTAFIAXPIDG-UHFFFAOYSA-K 0.000 description 1
- KOYYEPZTIWTHDY-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;zinc;dihydrate Chemical compound O.O.[Zn].[Zn].[Zn].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O KOYYEPZTIWTHDY-UHFFFAOYSA-N 0.000 description 1
- TWURVFFNODFJBJ-UHFFFAOYSA-N 4-[[1-[[1-[2-[(1-benzylsulfanyl-1-oxo-3-phenylpropan-2-yl)carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)SCC=1C=CC=CC=1)CC1=CC=CC=C1 TWURVFFNODFJBJ-UHFFFAOYSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N 7-Dehydrocholesterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- QGAVSDVURUSLQK-UHFFFAOYSA-N Ammonium heptamolybdate Chemical compound N.N.N.N.N.N.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Mo].[Mo].[Mo].[Mo].[Mo].[Mo].[Mo] QGAVSDVURUSLQK-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000004958 Brain cells Anatomy 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 229960004256 Calcium Citrate Drugs 0.000 description 1
- 229960004494 Calcium Gluconate Drugs 0.000 description 1
- 229940095618 Calcium Glycerophosphate Drugs 0.000 description 1
- 229940016114 Calcium Malate Drugs 0.000 description 1
- 229940095672 Calcium Sulfate Drugs 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L Calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 229940047036 Calcium ascorbate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H Calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- NEEHYRZPVYRGPP-IYEMJOQQSA-L Calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L Calcium glycerylphosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- OLOZVPHKXALCRI-UHFFFAOYSA-L Calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940108925 Copper Gluconate Drugs 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000002925 Dental Caries Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MHJAJDCZWVHCPF-UHFFFAOYSA-L Dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 description 1
- 102000004669 EC 1.4.3.13 Human genes 0.000 description 1
- 108010003894 EC 1.4.3.13 Proteins 0.000 description 1
- 108091003147 Electron Transport Complex IV Proteins 0.000 description 1
- 102000011686 Electron Transport Complex IV Human genes 0.000 description 1
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
- DNVPQKQSNYMLRS-APGDWVJJSA-N Ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-APGDWVJJSA-N 0.000 description 1
- DNVPQKQSNYMLRS-LNHMRCHQSA-N Ergosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3C([C@H]4[C@@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)=CC=2)CC1 DNVPQKQSNYMLRS-LNHMRCHQSA-N 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 210000003608 Feces Anatomy 0.000 description 1
- 229940063755 Folic Acid 0.1 MG Drugs 0.000 description 1
- 229940089653 Folic Acid 0.3 MG Drugs 0.000 description 1
- 229940083563 Folic Acid 1 MG Drugs 0.000 description 1
- 108060003412 GRP Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010062060 Hyperlipidaemia Diseases 0.000 description 1
- 206010020993 Hypoglycaemia Diseases 0.000 description 1
- 102100013321 INSR Human genes 0.000 description 1
- 101710010714 INSR Proteins 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 206010022972 Iron deficiency anaemia Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 229960003035 MAGNESIUM GLUCONATE Drugs 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L MANGANESE CHLORIDE Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229940072543 MANGANESE GLUCONATE Drugs 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- CTUVIUYTHWPELF-IYEMJOQQSA-L Magnesium gluconate Chemical compound [Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CTUVIUYTHWPELF-IYEMJOQQSA-L 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H Magnesium phosphate tribasic Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- 230000036091 Metabolic activity Effects 0.000 description 1
- 229960004452 Methionine Drugs 0.000 description 1
- VLAPMBHFAWRUQP-UHFFFAOYSA-L Molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 1
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 210000004165 Myocardium Anatomy 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 229940053487 Niacinamide Drugs 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 229960002477 Riboflavin Drugs 0.000 description 1
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000007442 Ricket Diseases 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- 229940055619 Selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-REOHCLBHSA-N Selenocysteine Chemical compound [SeH]C[C@H](N)C(O)=O ZKZBPNGNEQAJSX-REOHCLBHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 229960002718 Selenomethionine Drugs 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L Sodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 108010058254 Steroid 12-alpha-Hydroxylase Proteins 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 210000004243 Sweat Anatomy 0.000 description 1
- 229960003080 Taurine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 229940068475 ZINC CITRATE Drugs 0.000 description 1
- 229960000314 Zinc Acetate Drugs 0.000 description 1
- 229960000306 Zinc Gluconate Drugs 0.000 description 1
- 229960001296 Zinc Oxide Drugs 0.000 description 1
- DJWUNCQRNNEAKC-UHFFFAOYSA-L Zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L Zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000000170 anti-cariogenic Effects 0.000 description 1
- 230000002421 anti-septic Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001362 calcium malate Substances 0.000 description 1
- 235000013962 calcium malate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 229960000359 chromic chloride Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- UBFWAFZODRGFIF-UHFFFAOYSA-N cyanic acid;selenium Chemical compound [Se].OC#N UBFWAFZODRGFIF-UHFFFAOYSA-N 0.000 description 1
- 201000005705 deficiency anemia Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- LILHXQCLSOZSRO-UHFFFAOYSA-J dizinc;oxozinc;dicarbonate;tetrahydrate Chemical compound O.O.O.O.[Zn+2].[Zn+2].[Zn]=O.[Zn]=O.[Zn]=O.[O-]C([O-])=O.[O-]C([O-])=O LILHXQCLSOZSRO-UHFFFAOYSA-J 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002218 hypoglycaemic Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002428 insect molting hormone Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011776 magnesium carbonate Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 239000011742 magnesium glycerophosphate Substances 0.000 description 1
- 235000001130 magnesium glycerophosphate Nutrition 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 239000011584 manganese glycerophosphate Substances 0.000 description 1
- 235000018348 manganese glycerophosphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L phosphate Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004977 physiological function Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000000607 poisoning Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-O serotonin cation Chemical compound C1=C(O)C=C2C(CC[NH3+])=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-O 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229940110280 zinc methionine Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Abstract
一种用降低血糖的药物组合物,该组合物包括桑叶、维生素A、β-胡萝卜素、复合维生素B、维生素C、维生素D、维生素E和常量元素钙、镁及微量元素锌、硒、铬、铜、钼、锰,主要适用于高血糖人群,在降低血糖方面很有效,可长期施用或按疗程施用。
Description
用于降低血糖的药物组合物
技术领域:本发明涉及医药保健品技术领域,尤其是用于降低血糖的药物 组合物。
背景技术:该组合物包括桑叶、维生素A、 e-胡萝卜素、复合维生素B、
维生素C、维生素D、维生素E和常量元素钙、镁及微量元素锌、硒、铬、铜、
钼、锰。
桑叶为解表类天然中药材,经现代药理研究证实桑叶对多种原因引起的动 物高血糖均有降糖作用,所含脱皮固酮能促进葡萄糖转化为糖元,但不影响正 常动物血糖水平,脱皮激素还能降低血脂水平,对人体能促进蛋白质合成,排 除胆固醇,降低血脂。
维生素A也称视黄醇,有提高视力、防止夜盲的作用,参与糖原和蛋白质
的合成,能促进粘多糖合成,影响骨组织的更新、发育,使长骨向双端生长,
P-胡萝卜素在体内酶的作用下可转变为维生素A,发挥维生素A的作用,0-胡萝卜素具有与维生素E、维生素C以协同互补的方式抑制LDL胆固醇氧化反 应的作用。
B族维生素参与机体内蛋白质、脂肪和糖代谢,使脑细胞的兴奋和抑制处 于平衡状态,它包括维生素Bn维生素B2、烟酰胺、泛酸、生物素、维生素 B6、维生素Bu、叶酸等,在体内协同发挥生理作用。维生素Bi参与体内蛋白 质、脂肪、碳水化合物的分解代谢和合成代谢,缺乏时可致以脚气病为代表的 各种代谢障碍,此外维生素Bi还参与神经冲动反应,维持心肌正常功能,维持正常食欲,胃肠蠕动和消化液分泌等;维生素B2又名核黄素,是机体中许多重 要辅酶的组成部分,参与体内的物质代谢,保证体内氧化还原反应和能量生成, 参与体内抗氧化防御系统,缺乏时主要表现口腔生殖系统综合症、生长障碍、 缺铁性贫血、湿性皮炎、减少红细胞生成、影响神经系统功能、降低视力等; 烟酰胺又称尼克酰胺或维生素PP,其生理功能是参与体内新陈代谢,维持正常 神经系统功能,保证性激素等的合成,缺乏时可发生癞皮病,主要表现为皮炎、 腹泻、痴呆三大症状;泛酸在每一生物体内广泛存在,参与广泛的代谢活动, 已知有70多种酶在催化机体各类生物化学反应中都需要泛酸参与,否则便会代 谢失调;生物素也是一种B族维生素,与其它B族维生素协调参与人体物质和 能量代谢,它与核酸的合成,性激素的合成关系密切,它还具有防治白发、秃 头的功效;维生素B6在体内起转氨酶、氨基酸脱羧酶的辅酶作用,保证氨基酸、 糖原、脂肪酸及一碳单位、烟酸等物质的新陈代谢,保证核酸和蛋白质的合成 与细胞的正常增殖,保证与一羟色胺、牛磺酸、多巴胺等神经递质的正常代谢, 保证正常的免疫功能,缺乏时免疫力下降,还可造成神经系统的损害;维生素 Bu参与体内核酸,胆碱,氨基酸的合成及脂肪与糖的代谢,对骨髓造血功能, 消化道上皮细胞功能,肝脏功能和神经系统髓鞘功能的完整有一定作用,它是 发挥正常智力所必须的维生素,如果缺乏不仅造成智力障碍,还会出现营养性 贫血,影响对脑中血液供给;叶酸参与氨基酸和核酸的合成,并与维生素B12 共同促进细胞的生成与成熟,缺乏时正常细胞不能进行有丝分裂,会出现神经 病学的症状,如:记忆丧失,抑郁症及痴呆症等;
维生素C又称抗坏血酸,维生素C与胶原的关系密切,不仅有软化血管作 用,还有净化血液的作用,防止动脉硬化,在胆固醇代谢中起重要作用,可有 效降低中性脂肪,还能促进人体对食物中铁的吸收,为血细胞生成提供必需的原料,同时,维生素C在恢复体力、消除疲劳、缓解紧张情绪等方面作用明显;
维生素D是甾醇类衍生物,人体皮下脱氢胆固醇经紫外线照射产生维生素 D3,麦角固醇经紫外线照射后产生维生素D2, 二者来源不同,功能一致,在人 类营养中维生素D的重要性在于调节钙和磷的代谢作用;维生素D促进钙在小 肠吸收,缺乏维生素D则大量钙由粪便排出,从而引起人体缺钙,儿童会发生 佝偻病,成人体内贮存的钙磷耗尽会引起软骨病,最常见的软骨病人群是孕妇、 乳母和老年人。
维生素E是所有具有(i-生育酚生物活性的色酮衍生物的统称,其中a-生 育酚的活性最高,具有抗氧化,避免生物膜发生脂质过氧化反应的作用;阻止 低密度脂蛋白氧化形成的作用,从而防止动脉粥样硬化和心血管疾病的发生; 此外还有调节免疫、延缓衰老、抑制肿瘤、促进胚胎发育和生殖能力及对神经 和骨骼的保护作用等。
钙是人体重要的常量元素,主要起两方面的作用, 一是构成骨齿等硬组织, 二是与蛋白质结合或以钙离子的形式构成有特定功能的物质,形成所谓混溶钙 池与骨齿中转维持动态平衡,体内所有的细胞均需要钙才能发挥其正常功能; 缺钙还会引起内分泌功能紊乱及细胞生长调节失灵。
镁在人体内最主要的功能是遏制自由基的产生,自由基是促衰老的因素, 也是主要致出生缺陷的因素;镁的另一项功能是与钙和维生素D —起发挥保护 骨骼的作用,缺镁容易发生骨质疏松症,容易发生骨折;此外镁还有保护心脏 和防治糖尿病的功能等。
微量元素锌被融合在生物大分子配位体——蛋白质、核酸、膜(主要为膜 蛋白)中,生成稳定的含金属的生物大分子络合物——金属蛋白、金属核酸络 合物等,目前,己知这些物质参与碳水化合物、脂类、蛋白质及核酸的合成和降解过程,在六大类酶中都有含锌酶的存在;锌也是增强免疫活力的主要元素; 锌能通过激活羧肽酶B促进胰岛素原转化为胰岛素,缺锌使胰岛素在外周组织 的活性受阻,致糖耐量曲线异常。
微量元素硒有明显降低血清总胆固醇、甘油三酯和脂质过氧化物,提高髙 密度脂蛋白,加速体内多余脂肪代谢的作用;硒还具有强抗氧化功能,保护胚 胎不受超氧化物的伤害,预防心脏病;通过增强免疫识别系统清除癌细胞而抗 癌;解除和排泄重金属离子,对汞、甲基汞、镉、铅等有解毒作用,而重金属 污染是主要致出生缺陷因素;缺硒可使人体胰岛素分泌减少,糖耐量减低,抗 氧化能力下降而加速人体衰老和智力下降。
铬是胰岛素的"协同激素",以具有活性的含铬有机化合物"葡萄糖耐受因 子(GTF)"形式增强胰岛素的作用,主要是维持机体正常的糖代谢及脂代谢, 不足时会出现以下症状:削弱葡萄糖耐量、加重髙血糖症、尿糖、低血糖症、 加速胰岛素循环、减少胰岛素受体数量、降低胰岛素结合能力、体重减轻、增 加脂肪含量、增加视觉压力等。环境中稳定存在两种价态的铬,即三价铬和六 价铬,三价铬具有生理活性,在适量的范围内施用有益无害,六价铬是一种强 氧化剂,对人体具有毒副作用。
铜是体内赖氨酸氧化酶、细胞色素氧化酶、单胺氧化酶等30多种酶的活性 成分,参与细胞的氧化还原反应。缺铜时,催化胆固醇转变为胆酸的7d-羟酶 和12d-羟化酶活性降低,胆固醇合成和消除减少,胆固醇排出受阻,导致高脂 血症。绝对或相对铜缺乏可使血清TC、 TG水平升高,引起高胆固醇症。
钼是人体必需微量元素之一,它是多种酶的构成元素,参与铁的利用,促 进红细胞的发育和成熟,可预防贫血,并能帮助碳水化合物和脂肪的代谢,它 参与解除人体内有毒醛类的毒害,消除人体自由基,具有抗癌、抗衰老,增强免疫力及防龋齿的功能;缺钼可诱发心血管疾病、癌症及龋齿。
锰在人体内参与一些酶的构成,它不仅参与糖和脂类的代谢,而且在蛋白
质、DNA和RNA合成中均起作用。
应用含有桑叶、维生素A、 e-胡萝卜素、维生素Bp维生素B2、维生素
B6、烟酰胺、泛酸、生物素、维生素Bu、叶酸、维生素C、维生素D、维生素
E和常量元素钙、镁及微量元素锌、硒、铬、铜、钼、锰作为有效组分的组合
物已为人所知,但将桑叶、维生素A、 e-胡萝卜素、维生素Bp维生素B2、烟
酰胺、泛酸、生物素、维生素B6、维生素B^、叶酸、维生素C、维生素D、维
生素E和常量元素钙、镁及微量元素锌、硒、铬、铜、钼、锰配伍用于降低血
糖的药物组合物尚未报道。
当前用于降低血糖的药品或保健食品种类有多种,但有副作用的药品较多,
保健食品靶点少,环节欠缺,需要完善,并且成本高,售价高。
发明内容:为了克服现有降低血糖药物的缺点和不足,本发明的目的是提
供一种组合物,该组合物通过桑叶协同增加维生素A、 e-胡萝卜素、维生素Bi、
维生素B2、维生素B6、烟酰胺、泛酸、生物素、维生素Bu、叶酸、维生素C、
维生素D、维生素E和常量元素钙、镁及微量元素锌、硒、铬、铜、钼、锰降
低血糖之功效,同时通过常量元素钙、镁和微量元素锌、硒、铬、铜、钼、锰
及维生素A、 e-胡萝卜素、维生素Bp维生素B2、烟酰胺、泛酸、生物素、维
生素B6、维生素Bu、叶酸、维生素C、维生素D、维生素E,补充和增强桑叶
降低血糖的效果,即使长期施用也没有任何副作用;由于广泛研究的结果,本
发明人发现了桑叶和维生素A、 e-胡萝卜素、维生素Bp维生素B2、烟酰胺、
泛酸、生物素、维生素B6、维生素B12、叶酸、维生素C、维生素D维生素E与常量元素钙、镁及微量元素锌、硒、铬、铜、钼、锰的新型组合,这一新型
组合对于降低血糖有协同效果;而单用桑叶和维生素A、 P-胡萝卜素、复合维 生素B、维生素C、维生素D、维生素E与常量元素钙、镁及微量元素锌、硒、 络、铜、钼、锰,其效果均不及本组合物;本组合物不存在配伍禁忌,无毒副 作用,并且成本低,从而构成本发明。
本发明提供了用于降低血糖的药物组合物,它包括作为有效组分的桑叶和
维生素A、 e-胡萝卜素、维生素Bp维生素B2、烟酰胺、泛酸、生物素、维生
素B6、维生素B12、叶酸、维生素C、维生素D、维生素E与常量元素钙、镁
及微量元素锌、硒、铬、铜、钼、锰。
桑叶在国内的药材市场均有销售,其提取物也有专业生产厂和供货商,本
发明所用桑叶用其提取物作为原料。
用于本发明的维生素B! (VitaminBO、维生素B2 (VitaminB2)、烟酰胺 (Mcotinamide)、泛酸(Pantothenic Acid)、生物素(Vitamin H)、维生素B6 (VitaminB6)、维生素B12 (VitaminB12)、叶酸(Folic Acid),维生素C (Vitamin C)、均是水溶性维生素,在体内没有蓄积;维生素A (Vitamin A)、维生素 D(VitaminD)、维生素E (Vitamin E)是脂溶性维生素,0-胡萝卜素(Beta Carotene)是维生素A的前体物质,按本发明所用剂量有益无害;锌(Zn)、 硒(Se)、铬(Cr)、铜(Cu)、钼(Mo)为人体必需微量元素,锰(Mn)为 人体可能必需微量元素,钙(Ca)、镁(Mg)是人体必需的常量元素;本发明中 的常量元素钙可选用葡萄糖酸钙、乳酸钙、醋酸钙、酪蛋白钙、氯化钙、柠檬酸钙、苹果酸钙、柠檬酸苹果酸钙、磷酸氢钙、磷酸二氢钙、磷酸钙、硫酸钙、 抗坏血酸铐、甘油磷酸钙、碳酸钙等,常量元素镁可选用氯化镁、葡萄糖酸镁、 柠檬酸镁、磷酸氢镁、磷酸镁、甘油磷酸镁、乳酸镁、碳酸镁等,微量元素锌 可选用柠檬酸锌、醋酸锌、碳酸锌、氧化锌、氯化锌、乳酸锌、硫酸锌、葡萄 糖酸锌、单蛋氨酸锌等,微量元素硒可选用硒蛋氨酸、甲氧基苄氰酸硒、次苯 基双氰酸硒、硒化卡拉胶、半胱氨酸硒、硒化甲硫氨酸、亚硒酸钠、硒酸钠等, 微量元素铬可选用三氯化铬、烟酸铬、吡啶甲酸铬、铬酵母等三价铬,微量元 素铜可选用碳酸铜、柠檬酸铜、葡萄糖酸铜、硫酸铜等,微量元素钼可选用钼 酸铵、钼酸钠等,微量元素锰可选用硫酸锰、氯化锰、葡萄糖酸锰、甘油磷酸 锰、柠檬酸锰等,均有专业生产厂及供货商。
本发明的组合物主要适用于高血糖人群,按本发明,桑叶的有效用量以整
体天然药材计对成人来说为3000—30000mg/天,维生素Bi的有效用量为0.5— 20mg/天,维生素B2的有效用量为0.5—20mg/天,烟酰胺的有效用量为5""50mg/ 天,泛酸的有效用量为2—20mg/天,生物素的有效用量为0.01—0.1mg/天,维 生素B6的有效用量为0.5—10mg/天,维生素B12的有效用量为0.001—0.025mg/ 天,叶酸的有效用量为0.1—lmg/天,维生素C的有效用量为30—500mg/天, 维生素A和/或0 -胡萝卜素的有效用量(以视黄醇当量计)为250~800 u gRE/天; 维生素D的有效用量为0.0015—0.01mg/天,维生素E的有效用量(以a -生育酚 当量计)为5—150mga-TE/天,常量元素钙的有效用量以元素钙计为250—1000mg/天,镁的有效用量以元素镁计为100—300mg/天,微量元素锌的有效用 量以元素锌计为5—20mg/天,硒的有效用量以元素硒计为0.015"0.1mg/天,格 的有效用量以元素铬计为0.015—0.15mg/天,铜的有效用量以元素铜计为0.5— 1.5mg/天,钼的有效用量以元素钼计为0.02"0.06mg/天,锰的有效用量以元素 锰计为l一3mg/天。
本发明的组合物可按下列药物制剂形式施药或直接服用,例如,口服制剂 (如颗粒、粉末、胶囊、丸、片、干糖浆、液态制剂),或食物如固体食物(如 饼干),是与其它已知的添加剂混合而制备的,这类添加剂例如:载体、崩解剂、
缓释剂、赋形剂、填充剂、包覆剂、粘结剂、润滑剂、抗氧剂、涂覆剂、着色 剂、矫味剂、甜味剂、蔗糖替代品、营养强化剂、香味剂、表面活性剂、增塑 剂、PH调节剂、清新剂、悬浮剂、消泡剂、防腐剂、增稠剂、增溶助剂等,按 通常的方法进行制备或者将它们作为功能性组分或添加剂加入食物。
按本发明,桑叶、维生素A、 e-胡萝卜素、维生素Bp维生素B2、烟酰胺、 泛酸、生物素、维生素B6、维生素Bu、叶酸、维生素C、维生素D、维生素E 和常量元素钙、镁及微量元素锌、硒、铬、铜、钼、锰各组份可分别制剂,施
本发明的优点是本组合物从多环节、多系统、多靶点协同发挥降低血糖的 作用,对降低血糖有显著的效果,原料来源充足,成本低,组合物中各组分无 毒副作用,无配伍禁忌。附表1为本组合物与桑叶组份和维生素加元素组份对四氧嘧啶致糖尿病模 型小鼠降血糖试验效果比较。
下面将参考实施例及测试实施例效果比较列表来详细叙述本发明。
实施例1:
桑叶 5400mg,
维生素Bi 3mg,
维生素B2 3mg,
维生素B6 2mg,
烟酰胺 10mg,
维生素C 30mg,
乳酸锌(以微量元素锌计) 10mg,
硒酸钠(以微量元素硒计) 0.02mg,
烟酸铬(以微量元素格计) 0.08mg,
氯化镁(以微量元素镁计) 250mg,
维生素E (以a-生育酚当量计) 10mga-TE。
将上述组分进一步与适当量的添加剂如硅铝酸镁、聚溶剂化物60和丙二醇均匀地混合,将所得混合物均匀地填入胶囊而得9颗胶囊,每日3次,每次3
颗胶囊(
实施例2:
桑叶
维生素Bi 维生素B2 维生素B6 烟酰胺 维生素C
乳酸锌(以微量元素锌计) 硒酸钠(以微量元素硒计) 吡啶甲酸铬(以微量元素铬计) 柠檬酸铜(以微量元素铜计) 乳酸镁(以元素镁计) 维生素E (以a-生育酚当量计)
6000mg,
3mg,
3mg,
2mg,
10mg,
90mg,
8mg,
0.02mg,
0.06mg,
0.9mg,
200mg,
10mga-TE'
将上述组分进一步与适当量的添加剂如硅铝酸镁、聚溶剂化物60和丙二醇 均匀地混合,将所得混合物均匀地填入胶囊而得9颗胶囊,每日3次,每次3颗胶,
实施例3:
桑叶
维生素Bi
维生素B2
维生素B6
烟酰胺
维生素C
乳酸锌(以微量元素锌计)
硒酸钠(以微量元素硒计)
铬酵母(以微量元素铬计)
柠檬酸铜(以微量元素铜计)
钼酸纳(以微量元素钼计)
柠檬酸镁(以微量元素镁计)
维生素E (以a-生育酚当量计)
7000mg, 3mg,
2mg,
10mg,
30mg,
10mg,
0.02mg,
0.02mg,
0.8mg,
0.05mg,
180mg,
10mga-TE«
将上述组分进一步与适当量的添加剂如硅铝酸镁、聚溶剂化物60和丙二醇 均匀地混合,将所得混合物均匀地填入胶囊而得9颗胶囊,每日3次,每次3实施例4:
桑叶
维生素Bi 维生素B2 维生素B6 烟酰胺 维生素C
乳酸锌(以微量元素锌计) 硒酸钠(以微量元素硒计) 铬酵母(以微量元素络计) 柠檬酸铜(以微量元素铜计) 钼酸钠(以微量元素钼计) 柠檬酸锰(以微量元素锰计) 乳酸镁(以元素镁计) 维生素E (以a-生育酚当量计)
7500mg,
3mg,
3mg,
2mg,
10mg,
30mg,
10mg,
0.02mg,
0.02mg,
0.8mg,
0.03mg,
2mg,
200mg,
10mga-TE(
将上述组份进一步与适当量的添加剂如甘露糖醇、羟丙基纤维素、硅铝酸 镁和调味剂均匀地混合,再将所得混合物制成3包粒状物;每日服3次,每次服一包<
实施例5:
桑叶
维生素Bi
维生素82
维生素B6
烟酰胺
泛酸
生物素
维生素C
乳酸锌(以微量元素锌计) 硒酸钠(以微量元素硒计) 铬酵母(以微量元素铬计) 拧檬酸铜(以微量元素铜计) 钼酸钠(以微量元素钼计) 柠檬酸锰(以微量元素锰计) 乳酸镁(以元素镔计) 维生素E (以a-生育酚当量计)
8000mg,
3mg,
3mg,
2mg,
10mg,
12mg,
0.06mg,
30mg,
10mg,
0.02mg,
0.02mg,
0.8mg,
0.03mg,
2.5mg,
200mg,
10mga -TE(
将上述组份进一步与适当量的添加剂如甘露糖醇、羟丙基纤维素、硅铝酸 镁和调味剂均匀地混合,再将所得混合物制成3包粒状物;每日服3次,每次服一包。
实施例6:
桑叶 8500mg,
维生素B! 3mg,
维生素B2 3mg,
维生素B6 2mg,
叶酸 0.3mg,
维生素B12 0.003mg,
烟酰胺 10mg,
泛酸 2mg,
生物素 O.Olmg,
维生素C 30mg,
乳酸锌(以微量元素锌计) 10mg,
硒酸钠(以微量元素硒计) 0.02mg,
辂酵母(以微量元素铬计) 0.02mg,
柠檬酸铜(以微量元素铜计) 0.8mg,
钼酸钠(以微量元素钼计) 0.03mg,
柠檬酸锰(以微量元素锰计) 1.5mg,
乳酸镁(以元素镁计) 200mg,
维生素E (以a-生育酚当量计) 10mga-TE。
将上述组份进一步与适当量的添加剂如甘露糖醇、羟丙基纤维素、硅铝酸
镁和调味剂均匀地混合,再将所得混合物制成3包粒状物;每日服3次,每次服一包。
实施例7:
桑叶 3000mg,
维生素B! 0.5mg,
维生素B2 0.5mg,
维生素B6 0.5mg,
叶酸 O.lmg,
维生素B12 0.001mg,
烟酰胺 5mg,
泛酸 2mg,
生物素 0.01mg,
维生素C 30mg,
乳酸锌(以微量元素锌计) 5mg,
硒酸钠(以微量元素硒计) 0.015mg,
铬酵母(以微量元素铬计) 0.015mg,
拧檬酸铜(以微量元素铜计) 0.5mg,
钼酸钠(以微量元素钼计) 0.02mg,
柠檬酸锰(以微量元素锰计) lmg,
乳酸钙(以元素钙计) 250mg,
乳酸镁(以元素镁计) 100mg,
视黄醇当量(维生素A和/或e-胡萝卜素)250ixgRE,
维生素D 0.0015mg,
维生素E (以a -生育酚当量计) 5mg a - TE。 将上述组份进一步与适当量的添加剂如甘露糖醇、羟丙基纤维素、硅铝酸 镁和调味剂均匀地混合,再将所得混合物制成3包粒状物;每日服3次,每次 服一包。实施例8:
桑叶 30000mg,
维生素Bi 20mg,
维生素B2 20mg,
维生素B6 10mg,
叶酸 lmg,
维生素B12 0.025mg,
烟酰胺 50mg,
泛酸 20mg,
生物素 O.lmg,
维生素C 500mg,
乳酸锌(以微量元素锌计) 20mg,
硒酸钠(以微量元素硒计) O.lmg,
铬酵母(以微量元素铬计) 0.15mg,
柠檬酸铜(以微量元素铜计) 1.5mg,
钼酸钠(以微量元素钼计) 0.06mg,
柠檬酸锰(以微量元素锰计) 3mg,
乳酸钙(以元素钙计) 1000mg,
乳酸镁(以元素镁计) 300mg, 视黄醇当量(维生素A和/或P-胡萝卜素)250ligRE,
维生素D O.Olmg,
维生素E (以a -生育酚当量计) 150mg a - TE。
将上述组份进一步与适当量的添加剂如甘露糖醇、羟丙基纤维素、硅铝酸 镁和调味剂均匀地混合,再将所得混合物制成3包粒状物;每日服3次,每次 服一包,连服10日,停服5日,再服10日。
经动物试验证实本组合物属无毒级;人群服用也未见毒副反应。
实施例9:本组合物与各组份对四氧嘧啶致糖尿病模型小鼠降血糖试验效果比较。
选昆明种小鼠60只,雄雌各半;其中48只小鼠雄雌各半,禁食16小时后, 尾静脉注射四氧嘧啶TOmg/kg", 72小时之后,测定空腹血糖值,血糖值髙于 16.7mmol/L"者为高血糖小鼠,根据血糖水平将高血糖小鼠分为4组:模型对 照组(B组),C组,D组,E组,试验各组按0.2mL/10g"体重灌胃给药连续 10天,第10天禁食7小时后灌胃给药,同法测定给药后l小时,2小时的血糖 值;余下的12只小鼠,作为正常对照组(A组),模型对照组与正常对照组每 天给等体积生理盐水灌胃 一次。
相关数据见附表l。
附表1:本组合物与桑叶组份和维生素加元素组份对四氧嘧啶致糖尿病模型 小鼠降血糖试验效果比较:
<table>table see original document page 26</column></row>
<table>
从表1中可明显看出,服用本组合物制剂与服用桑叶组份及维生素加元素
组份对比糖尿病模型小鼠降血糖试验效果有非常显著的差异。
Claims (7)
1、一种用于降低血糖的药物组合物,其特征是,它由下列原料药按下列重量配比制成: 桑叶 3000-30000mg, 维生素B1 0.5-20mg, 维生素B2 0.5-20mg, 维生素B6 0.5-10mg, 叶酸 0-1mg, 维生素B12 0-0.025mg, 烟酰胺 5-50mg, 泛酸 0-20mg, 生物素 0-0.1mg, 维生素C 30-500mg, 锌 5-20mg, 硒 0.015-0.1mg, 铬 0.015-0.15mg, 铜 0-1.5mg, 钼 0-0.06mg, 锰 0-3mg, 钙 0-1000mg, 镁 100-300mg, 视黄醇当量[维生素A和/或β-胡萝卜素] 0-800μgRE, 维生素D 0-0.01mg, 维生素E 5-150mg a-TE。
2、根据权利要求1所述的用于降低血糖的药物组合物,其特征是,它由下列原料药按下列重量配比制成:桑叶 3000—30000mg,维生素Bi 0.5—20mg,维生素B2 0.5—20mg,维生素B6 0.5—10mg,叶酸 0"lmg,维生素B12 0—0.025mg,烟酰胺 5—50mg,泛酸 0~20mg,生物素 0"0.1mg,维生素C 30—500mg,锌 5—20mg,硒 0.015~0.1mg,铬 0.015~0.15mg,铜 0.5—1.5mg,钼 0""0.06mg,锰 0—3mg,钙 0"1000mg,镁 100~300mg,视黄醇当量【维生素A和/或e-胡萝卜素】 0—800y gRE,维生素D 0"0.01mg, 维生素E 5—150mg a-TE。
3、根据权利要求l所述的用于降低血糖的药物组合物,其特征是,它由下列原料药按下列重量配比制成:桑叶 3000~30000mg,维生素Bi 0.5—20mg,维生素B2 0.5—20mg,维生素B6 0.5—10mg,叶酸 0~lmg,维生素B12 0""0.025mg,烟酰胺 5—50mg,泛酸 0"20mg,生物素 0"0.1mg,维生素c 30"500mg,锌 5—20mg,硒 0.015—O.lmg,铬 0.015—0.15mg,铜 0.5—1.5mg,钼 0.02—0.06mg, 0~3mg,钙 0~1000mg,镁 100~300mg,视黄醇当量【维生素A和/或e-胡萝卜素I 0—800lxgRE, 维生素D 0""0.01mg, 维生素E 5—150mg a-TE。
4、根据权利要求1所述的用于降低血糖的药物组合物,其特征是,它由下 列原料药按下列重量配比制成:桑叶 3000~30000mg,维生素Bi 0.5—20mg,维生素B2 0.5—20mg,维生素B6 0.5—10mg,叶酸 0~lmg,维生素B12 0"0.025mg,烟酰胺 5—50mg,泛酸 0—20mg,生物素 0"0.1mg,维生素c 30"500mg,锌 5—20mg,硒 0.015—O.lmg,铬 0.015—0.15mg,铜 0.5—1.5mg,钼 0.02—0.06mg, 1—3mg,钙 0—1000mg,镁 100~300mg, 视黄醇当量[维生素A和/或0 -胡萝卜素】0~800u gRE, 维生素D 0~0.01mg, 维生素E 5—150mg a-TE。
5、根据权利要求l所述的用于降低血糖的药物组合物,其特征是,它由下 列原料药按下列重量配比制成:桑叶 3000~30000mg,维生素B1 0.5—20mg,维生素B2 0.5—20mg,维生素B6 0.5—10mg,叶酸 0~lmg,维生素B12 0~0.025mg,烟酰胺 5—50mg,泛酸 2—20mg,生物素 0.01—O.lmg,维生素C 30~500mg,锌 5—20mg,硒 0.015—O.lmg,铬 0.015—0.15mg,铜 0.5—1.5mg,钼 0.02——0.06mg,锰 1—3mg,铐 0—1000mg,镁 100~~300mg, 视黄醇当量l维生素A和/或P -胡萝卜素l 0~800 u gRE,维生素D 0~0.01mg,维生素E 5—150mg a-TE。
6、根据权利要求l所述的用于降低血糖的药物组合物,其特征是,它由下列原料药按下列重量配比制成:桑叶 3000—30000mg,维生素Bi 0.5—20mg,维生素B2 0.5—20mg,维生素B6 0.5—10mg,叶酸 O.l—lmg,维生素B12 0.001~0.025mg,烟酰胺 5—50mg,泛酸 2—20mg,生物素 O.Ol—O.lmg,维生素C 30~500mg,锌 5—20mg,硒 0.015—0.1mg,铬 0.015""0.15mg,铜 0.5—1.5mg,钼 0.02—0.06mg,锰 1—3mg,转 0"1000mg,镁 100—300mg, 视黄醇当量[维生素A和/或0 -胡萝卜素】0~800 u gRE,维生素D 0~0.01mg,维生素E 5—150mg a-TE。
7、根据权利要求1所述的用于降低血糖的药物组合物,其特征是,它由下 列原料药按下列重量配比制成:桑叶 300(H"30000mg,维生素Bi 0.5—20mg,维生素B2 0.5—20mg,维生素B6 0.5—10mg,叶酸 0.1—lmg,维生素B12 0.001~0.025mg,烟酰胺 5—50mg,泛酸 2—20mg,生物素 0.01—O.lmg,维生素C 30"500mg,锌 5—20mg,硒 0.015—0.1mg,铬 0.015—0.15mg,铜 0.5—1.5mg,钼 0.02—0.06mg,锰 1—3mg,韩 250"1000mg,镁 100"300mg, 视黄醇当量[维生素A和/或e -胡萝卜素l 250~800 n gRE,维生素D 0.0015—0.01mg,维生素E 5—150mg a-TE。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910081657A CN101632714A (zh) | 2009-04-07 | 2009-04-07 | 用于降低血糖的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910081657A CN101632714A (zh) | 2009-04-07 | 2009-04-07 | 用于降低血糖的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101632714A true CN101632714A (zh) | 2010-01-27 |
Family
ID=41592151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910081657A Pending CN101632714A (zh) | 2009-04-07 | 2009-04-07 | 用于降低血糖的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101632714A (zh) |
-
2009
- 2009-04-07 CN CN200910081657A patent/CN101632714A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101642468A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101601681A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101574370A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101632790A (zh) | 用于降低血糖的药物组合物 | |
CN101574365A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101574406A (zh) | 用于降低血脂的药物组合物 | |
CN101574369A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101574368A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101574404A (zh) | 用于降低血脂的药物组合物 | |
CN101632714A (zh) | 用于降低血糖的药物组合物 | |
CN101574437A (zh) | 用于降低血糖的药物组合物 | |
CN101579444A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101632710A (zh) | 用于降低血糖的药物组合物 | |
CN101596210A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101569648A (zh) | 用于降低血糖的药物组合物 | |
CN101632715A (zh) | 用于降低血糖的药物组合物 | |
CN101574405A (zh) | 用于降低血脂的药物组合物 | |
CN101584727A (zh) | 用于降低血脂的药物组合物 | |
CN101579438A (zh) | 用于降低血糖的药物组合物 | |
CN101601726A (zh) | 用于降低血糖的药物组合物 | |
CN101632716A (zh) | 用于降低血糖的药物组合物 | |
CN101590150A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101569647A (zh) | 用于降低血糖的药物组合物 | |
CN101574434A (zh) | 用于降低血糖的药物组合物 | |
CN101596209A (zh) | 用于降低血糖和血脂的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100127 |